The trial results support Tukysa-Herceptin-Perjeta as yet another option for breast cancer patients in the frontline ...

The SERD improved survival endpoints compared to standard adjuvant endocrine therapy in a Phase III trial that may support ...

Challenging federal funding cuts, minimal residual disease, and a busy field of CAR T-cell candidates characterized this year ...

Researchers have given the gene therapy made at UManchester to two out of five planned patients in a Phase I/II trial, and ...

Researchers also discussed access barriers at the meeting, and a survey found distance was a major hindrance to CAR-T ...

Researchers at ASH shared Phase III data comparing the pre- and five-year posttreatment adjusted annualized bleeding rates, ...

A new analysis presented at ASH found Black AML patients were five years younger, on average, than White patients, and less ...

Data presented at ASH suggest that the CRISPR therapy could provide a one-time functional cure in children as young as 5 ...

NEW YORK – TransCode Therapeutics' microRNA-10b inhibitor TTX-MC138 will be included in a Phase II branch of the PRE-I-SPY trial, the company announced Thursday.

The results mark a setback for the hypothesis that drugs like semaglutide could provide a neuroprotective effect for patients ...

A large international analysis found no adverse effect of menopausal hormonal therapy among women with high genetic cancer risks.

One study found frail patients tend to have worse survival outcomes on the therapy, but another challenged the idea that ...